NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company ...

VectorY Therapeutics (VectorY), a biotechnology company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, today announced that it will have four feat ...

ST. PAUL, Minn. — Truth be told, we’ll probably never know exactly what’s going through Marco Rossi’s head and the emotions flowing through his being. He’s too mature, too much of a pro ...

Additionally, the U.S. Food and Drug Administration (FDA) has acknowledged its receipt of the recently submitted Drug Master File (DMF) for the IsoTag™ AAV reagent, which will support and ...

Jalen Hurts currently ranks 10th in AAV at $51 million on his deal with the Philadelphia Eagles. Prescott is currently the only player making more than $55 million per season. Jordan Love ...

This in silico approach aims to increase the fitness of clinical adeno-associated virus (AAV) capsids to make gene therapies more economically viable for patients. Developing AAV capsids with ...

Future research should focus on illuminating how different interstitial lung disease subtypes affect outcomes in AAV. Interstitial lung disease (ILD) patterns differ between patients with ...

On this episode of GEN Live, we’ll talk to experts in delivery with a focus on AAV vectors. We’ll discuss the successes the field has experienced, the challenges that remain, new technologies ...

Treatment with fidanacogene elaparvovec, a recombinant adeno-associated virus (AAV) vector developed for the treatment of hemophilia B, led to sustained expression of the high-activity factor IX ...

A novel nanoneedle platform provides crucial insights by precisely quantifying AAV subpopulations—empty, partial, full, and overfilled capsids—at the molecular level, overcoming key ...